Увійти

Готові списки джерел за темами / 004.056.5; 57.087.2(043.2)

Зміст

Статті в журналах

Добірка наукової літератури з теми "004.056.5; 57.087.2(043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "004.056.5; 57.087.2(043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "004.056.5; 57.087.2(043.2)"

1

Tsimberidou, A. M., C. Tam, W. Wierda, S. O' Brien, S. Lerner, and M. J. Keating. "Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7034. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7034.

Повний текст джерела

Анотація:

7034 Introduction: High β2M levels are a risk factor in CLL. PCR therapy has been reported to be better tolerated than FCR in older or with decrease renal function pts (Shanafelt, Blood 108:15a). We assessed the association between age, CrCl, PS, β2M and outcomes in pts treated with FCR. Methods: From 7/99 to 1/04, 300 pts received rituximab 375 mg/m2 D1; fludarabine 25 mg/m2/d D2–3; and cyclophosphamide 250 mg/m2/d D2–3. Serum β2M levels were measured by radioimmunoassay. CrCl was calculated (Cockcroft-Gault equation). Results: The median age was 57 yrs (≥70, 14%). Age ≥70 was associated with

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Baron, Frederic, Myriam Labopin, Mohamad Mohty, et al. "Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT." Blood 114, no. 22 (2009): 3313. http://dx.doi.org/10.1182/blood.v114.22.3313.3313.

Повний текст джерела

Анотація:

Abstract Abstract 3313 Poster Board III-201 RIC allo-SCT has been increasingly used as treatment for AML patients (pts) ineligible for myeloablative allo-SCT. Previous studies have observed a lower risk of relapse in pts who experienced chronic GVHD after RIC allo-SCT versus in those who did not. The objective of the current study was to further investigate the association between chronic GVHD and relapse in a large cohort of pts given RIC allo-SCT as treatment for AML. Data from 1188 AML pts in first or second CR transplanted between 2000 and 2008 following a RIC regimen at EBMT affiliated ce

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Willasch, Andre Manfred, Christina Peters, Petr Sedlacek, et al. "Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study." Blood 130, Suppl_1 (2017): 911. http://dx.doi.org/10.1182/blood.v130.suppl_1.911.911.

Повний текст джерела

Анотація:

Abstract Introduction: Most pediatric patients (pts) with ALL receive total body irradiation (TBI) for myeloablative conditioning of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is unproven whether TBI can be replaced by chemotherapy (CHT). Methods: To compare the outcomes of TBI- versus (vs.) CHT-based conditioning, we performed a retrospective EBMT-registry based study. Children between 2 and 18 years of age (y.) after myeloablative conditioning for first allo-HSCT of bone marrow (BM) or peripheral blood SC (PBSC) from matched sibling (MSD) or unrelated donors (UD) in f

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Повний текст джерела

Анотація:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Della Porta, Matteo G., Emilio Paolo Alessandrino, Andrea Bacigalupo, et al. "The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making." Blood 122, no. 21 (2013): 2765. http://dx.doi.org/10.1182/blood.v122.21.2765.2765.

Повний текст джерела

Анотація:

Abstract Background The only curative treatment for patients with myelodysplastic syndrome (MDS) is allogeneic stem cell transplantation (allo-SCT). Decision to transplant is currently based on the International Prognostic Scoring System (IPSS), which has limitations. Recently, a revised IPSS (IPSS-R) has been developed (Blood. 2012;120:2454-2465). Aim To identify predictive factors for transplantation outcome, we studied 519 patients with MDS or acute myeloid leukemia (AML) evolving from MDS who received allo-SCT and were reported to the GITMO registry between 2000 and 2010. Results 1 Posttra

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Wang, Yu, and Xiao Jun Huang. "Donor Selection For Haploidentical Hematopoietic Stem Cell Transplantation: Who Is The Better – Donor-Recipient Risk Factor Analysis." Blood 122, no. 21 (2013): 705. http://dx.doi.org/10.1182/blood.v122.21.705.705.

Повний текст джерела

Анотація:

Abstract Background many aspects should be considered when selecting an ideal donor. The progress made in haploidentical HSCT in recent years offers almost unlimited donor and availabilities of more than one donor at many occasions. To date, there have been no studies to answer the question of apart from HLA disparity, whether one donor should be preferred over another among various haploidentical donors available. The goal of the current study was to attempt to answer the question by analyzing the data on haploidentical HSCT without in-vitro T cell depletion modality. Methods Consecutive pati

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Kuendgen, Andrea, Michael Lauseker, Alan F. List, et al. "Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study." Blood 118, no. 21 (2011): 119. http://dx.doi.org/10.1182/blood.v118.21.119.119.

Повний текст джерела

Анотація:

Abstract Abstract 119 Background: Lenalidomide (LEN) treatment resulted in RBC transfusion independence for ≥ 8 wks in 51–67% of patients (pts) and cytogenetic response in 25–73% of pts with lower-risk MDS and del5q in 2 large multicenter trials (MDS-003 and -004) (List A et al. NEJM 2006;355:1456–65; Fenaux P et al. Blood 2011; doi:10.1182/blood-2011-01-330126). However, these studies were either single-arm or allowed early crossover to LEN, thus data on the influence of LEN on AML progression and overall survival (OS) is lacking. Aims: To assess the risk of AML progression and death in LEN-t

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Nakayama, Y., R. Nakashima, T. Handa, et al. "POS1051 LUNG CLUSTERING ANALYSIS-BASED PHENOTYPES OF RHEUMATOID ARTHRITIS USING ARTIFICIAL INTELLIGENCE-BASED TECHNOLOGY FOR CHEST COMPUTED TOMOGRAPHY." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 843.1–844. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2178.

Повний текст джерела

Анотація:

BackgroundLung involvement is a prevalent extraarticular manifestation of rheumatoid arthritis (RA) that remains a significant clinical challenge. Few studies have comprehensively quantified lung abnormalities of RA patients using artificial intelligence-based (AI) technology.ObjectivesThe aim of this study was to quantify lung lesions in RA patients and classify them based on their lung parameters.MethodsAn AI-based quantitative computed tomography (CT) image analysis software (AIQCT) was applied to high-resolution CT scans of RA patients in a cross-sectional manner. AIQCT automatically class

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Lasa, Marta, Mario Nuvolone, Ioannis V. Kostopoulos, et al. "Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis." Blood 144, Supplement 1 (2024): 889. https://doi.org/10.1182/blood-2024-202995.

Повний текст джерела

Анотація:

Background: Novel treatments targeting the plasma cell clone are increasing the rate of hematologic complete response (CR) and improving outcomes in AL amyloidosis. In multiple myeloma (MM), MRD negativity is considered the new CR and pivoted from a prognostic factor into a treatment endpoint and a surrogate for accelerated drug approval. By contrast, the role of MRD in AL amyloidosis remains uncertain and, accordingly, it is not routinely performed in clinical trials and practice. Aim: Investigate the clinical significance of MRD assessment in patients with AL amyloidosis. Methods: This multi

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Dörner, T., Y. Tanaka, M. Mosca, et al. "POS0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 639.1–639. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2375.

Повний текст джерела

Анотація:

BackgroundBaricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE).ObjectivesTo assess the safety profile of BARI in patients with SLE.MethodsPatients with SLE receiving stable background therapy were randomised 1:1:1 to BARI 2-mg, 4-mg, or placebo (PBO) once daily in one 24-week, phase 2 (NCT02708095) and two 52-week, phase 3, PBO controlled studies (NCT03616912 and NCT03616964).ResultsA total of 1,849 patients were

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!